Eylea

Aflibercept, the active ingredient in Eylea, is a VEGF inhibitor presented as a 40 mg/ml solution for injection for intravitreal use. It is used to treat various eye conditions in adults, including neovascular age-related macular degeneration, macular edema secondary to retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. GNH USA supplies Eylea as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Eylea is designed to block the activity of vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF), which are involved in the abnormal growth of blood vessels in the eye. This helps to stabilize and, in many cases, improve vision loss related to the treated conditions.

Eylea is used to treat various eye conditions by inhibiting the growth of abnormal blood vessels in the eye. It is effective in managing the following conditions:

- Neovascular age-related macular degeneration: Helps to stabilize and improve vision loss due to the abnormal growth of blood vessels in the retina. - Macular edema secondary to retinal vein occlusion: Reduces swelling in the retina caused by blocked blood vessels, improving vision. - Diabetic macular edema: Decreases fluid leakage from blood vessels in the retina, reducing swelling and improving vision in diabetic patients. - Myopic choroidal neovascularization: Prevents the growth of abnormal blood vessels in the choroid, which can lead to vision loss in individuals with severe myopia.

Eylea, like all medications, can cause side effects. Common side effects include:

Common Side Effects: - Eye pain or redness at the injection site. - Floaters or spots in vision. - Increased intraocular pressure. - Conjunctival hemorrhage. - Cataracts. - Vitreous detachment.

Serious or Rare Side Effects: - Endophthalmitis (severe eye infection). - Retinal detachment. - Uveitis (inflammation of the eye). - Increased risk of arterial thromboembolic events (e.g., heart attack or stroke). - Allergic reactions.

Eylea should be used with caution and under the supervision of a healthcare professional. Important precautions include:

- Infection risk: There is an increased risk of eye infections, so the injection site must be kept clean. - Eye inflammation: Patients with a history of eye inflammation should be monitored closely. - Arterial thromboembolic events: Patients with a history of heart disease or stroke should be carefully evaluated before treatment. - Pregnancy: The safety of Eylea during pregnancy has not been established, and it should be used with caution. - Breastfeeding: It is not known whether aflibercept passes into breast milk, so caution is advised. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Eylea may interact with other medications, and these interactions should be carefully managed. Major interactions to avoid include:

Major Interactions (Avoid): - Other anti-VEGF agents: Concurrent use with other anti-VEGF treatments may increase the risk of adverse effects. - Immunosuppressants: May increase the risk of infections. - Corticosteroids: May enhance the risk of eye infections and inflammation.

Moderate Interactions (Monitor Closely): - Anticoagulants: May increase the risk of bleeding events. - Antiplatelet agents: May enhance the risk of bleeding. - Nonsteroidal anti-inflammatory drugs (NSAIDs): May increase the risk of eye inflammation.